ELI LILLY & Co (LLY) operating KPIs

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value

$1417.54+43.84 (+3.19%)

Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%

KPIs

Operating metrics that drive Eli Lilly's business · fiscal year ends December 31 (calendar fiscal year; FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.

Metric	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30

Consolidated revenue ($M)($M)5	22,974	19,799	19,292	17,601	15,558	12,729	13,533	11,439	11,303	8,768	9,353	9,499
Net product revenue ($M)($M)	21,403	18,453	18,300	16,331	14,726	11,601	12,025	10,572	10,355	7,797	8,290	7,306
Collaboration and other revenue ($M)($M)	1,571	1,346	992	1,270	832	1,127	1,508	868	948	972	1,064	2,192
Royalty revenue ($M) [reported separately through FY2023]($M)											105	31.3
Geographic revenue — United States ($M)($M)	14,413	12,119	12,877	11,300	10,814	8,489	9,032	7,814	7,835	5,694	6,455	5,368
Geographic revenue — Outside U.S. ($M)($M)4	8,561	7,680	6,415	6,301	4,743	4,239	4,501	3,626	3,468	3,074	2,898	4,131
Europe revenue ($M)($M)	4,115	3,646	3,097	3,498	2,574	2,389	2,448	1,628	1,404	1,441	1,338	2,569
Japan revenue ($M)($M)	628	571	655	555	521	402	559	429	463	364	439	391
China revenue ($M)($M)	941	693	473	560	466	451	429	460	395	376	377	391
Rest of World / Other foreign countries revenue ($M)($M)	2,877	2,771	2,190	1,688	1,182	997	1,064	1,108	1,206	893	744	780
Worldwide revenue growth YoY (%)(%)3	48.0%	56.0%	43.0%	54.0%	38.0%	45.0%	45.0%	20.0%	36.0%	26.0%	28.0%	37.0%
Worldwide volume growth impact YoY (%)(%)	60.0%	65.0%	46.0%	62.0%	42.0%	53.0%	48.0%	15.0%	27.0%	16.0%		31.0%
Worldwide realized price impact YoY (%)(%)	-13.0%	-13.0%	-5.0%	-10.0%	-6.0%	-6.0%	-4.0%	6.0%	10.0%	10.0%		6.0%
Worldwide foreign exchange impact YoY (%)(%)	1.0%	4.0%	4.0%	2.0%	1.0%	-2.0%		-1.0%	-1.0%			1.0%
U.S. revenue growth YoY (%)(%)2	33.0%	43.0%	43.0%	45.0%	38.0%	49.0%	40.0%	46.0%	42.0%	28.0%	39.0%	21.0%
U.S. volume growth impact YoY (%)(%)	37.0%	49.0%	50.0%	60.0%	46.0%	57.0%	45.0%	35.0%	27.0%	12.0%	12.0%	9.0%
U.S. realized price impact YoY (%)(%)	-3.0%	-7.0%	-7.0%	-15.0%	-8.0%	-7.0%	-5.0%	11.0%	15.0%	16.0%	-3.0%	13.0%
Outside U.S. revenue growth YoY (%)(%)3	80.0%	81.0%	43.0%	74.0%	37.0%	38.0%	55.0%	-12.0%	25.0%	22.0%	10.0%	64.0%
Outside U.S. volume growth impact YoY (%)(%)	113.0%	95.0%	38.0%	66.0%	35.0%	46.0%	56.0%	-10.0%	27.0%	23.0%	10.0%	69.0%
Outside U.S. realized price impact YoY (%) [Q1–Q3 10-Q & FY 10-K](%)	-36.0%	-25.0%		3.0%	-1.0%	-3.0%				-1.0%	-3.0%	-7.0%
Outside U.S. foreign exchange impact YoY (%)(%)	4.0%	11.0%	4.0%	6.0%	3.0%	-5.0%		-1.0%	-3.0%		3.0%	2.0%

Cardiometabolic Health — U.S. revenue ($M)($M)1	11,742	9,924	10,057	8,867	8,363	6,577	6,527	5,517	5,716	4,090	4,465	3,460
Cardiometabolic Health — Outside U.S. revenue ($M)($M)	6,611	5,836	4,436	4,311	2,980	2,631	2,579	1,890	1,799	1,403	1,282	1,260
Mounjaro (tirzepatide — Type 2 diabetes & international obesity) — Worldwide revenue ($M)($M)3	9,943	8,662	7,409	6,515	5,199	3,842	3,530	3,113	3,091	1,807	2,206	1,409
Mounjaro — U.S. revenue ($M)($M)	4,791	4,232	4,143	3,550	3,302	2,656	2,631	2,385	2,414	1,520	2,105	1,277
Mounjaro — Outside U.S. revenue ($M)($M)	5,152	4,430	3,267	2,965	1,897	1,186	899	728	677	286	101	132
Mounjaro — Worldwide revenue growth YoY (%)(%)	91.0%	125.0%	110.0%	109.0%	68.0%	113.0%	60.0%	132.4%	64.0%	32.0%		90.0%
Zepbound (tirzepatide — Obesity & obstructive sleep apnea) — Worldwide revenue ($M)($M)3	4,928	4,160	4,261	3,588	3,381	2,312	1,907	1,258	1,243	517	176	0
Zepbound — U.S. revenue ($M)($M)	4,873	4,134	4,230	3,568	3,380	2,305	1,908	1,258	1,243	517	176	0
Zepbound — Outside U.S. revenue ($M)($M)	55	26	30.3	19.8	2	7	0	0	0	0	0	0
Zepbound — Worldwide revenue growth YoY (%)(%)	46.0%	80.0%	123.0%	185.0%	172.0%
Trulicity (dulaglutide) — U.S. revenue ($M)($M)3	908	600	693	707	744	771	800	935	877	1,082	1,255	1,259
Trulicity — Outside U.S. revenue ($M)($M)	312	318	344	345	348	325	451	366	369	374	413	415
Trulicity — Worldwide revenue ($M) [Q1–Q3 10-Q & FY through FY2024]($M)	1,219	919		1,052	1,092	1,095	1,250	1,301	1,246	1,456	1,669	1,674
Trulicity — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%)	12.0%	-16.0%		366.0%	368.9%	374.4%	-25.0%	-22.0%	-31.0%	-26.0%	-14.0%	-10.0%
Jardiance (empagliflozin, incl. Glyxambi, Synjardy & Trijardy XR) — Worldwide revenue ($M)($M)4	1,232	1,114	769	959	690	1,014	1,199	686	770	687	798	701
Jardiance — U.S. revenue ($M)($M)	616	512	466	424	382	310	465	336	429	368	469	416
Jardiance — Outside U.S. revenue ($M)($M)	615	602	302	535	308	705	734	351	341	318	329	285
Jardiance commercial milestone collaboration revenue ($M)($M)	250	250	0	200	0	370
Jardiance — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%)	79.0%	10.0%		350.5%	340.7%	318.3%	50.0%	-2.0%	15.0%	19.0%	30.0%	22.0%
Other Cardiometabolic Health medicines — U.S. revenue ($M)($M)1	554	446	525	618	556	535	723	603	754	602	2,607	53.2
Other Cardiometabolic Health medicines — Outside U.S. revenue ($M)($M)	477	460	492	446	425	410	496	446	412	424	1,454	88.6
Oncology — U.S. revenue ($M)($M)2	1,473	1,228	1,512	1,375	1,419	1,046	1,468	1,294	1,275	998	1,107	1,002
Oncology — Outside U.S. revenue ($M)($M)	1,097	1,040	1,095	1,033	994	902	1,084	938	884	812	777	746
Oncology — Worldwide revenue ($M) [legacy total]($M)	2,570	2,268		2,408	2,414	1,948		2,232	2,159	1,810		1,747
Verzenio (abemaciclib) — Worldwide revenue ($M)($M)3	1,474	1,302	1,604	1,470	1,489	1,159	1,555	1,369	1,332	1,050	1,145	1,040
Verzenio — U.S. revenue ($M)($M)	845	706	997	880	929	658	1,043	879	861	638	775	685
Verzenio — Outside U.S. revenue ($M)($M)	629	596	608	590	560	501	513	490	471	412	370	356
Verzenio — Worldwide revenue growth YoY (%)(%)	-1.0%	12.0%	3.0%	7.0%	12.0%	10.0%	36.0%	32.0%	44.0%	40.0%	42.0%	68.0%
Other Oncology medicines — U.S. revenue ($M)($M)1	628	522	515	495	490	388	426	416	414	360	1,034	95
Other Oncology medicines — Outside U.S. revenue ($M)($M)	468	444	488	443	434	400	572	447	413	400	1,152	119
Immunology — U.S. revenue ($M)($M)2	790	619	912	773	701	578	767	694	600	397	605	575
Immunology — Outside U.S. revenue ($M)($M)	627	584	629	589	555	510	524	492	483	437	499	412
Immunology — Worldwide revenue ($M) [legacy total]($M)	1,417	1,203		1,362	1,256	1,088		1,186	1,082	834		987
Taltz (ixekizumab) — U.S. revenue ($M)($M)3	539	417	724	583	549	477	665	600	539	347	538	509
Taltz — Outside U.S. revenue ($M)($M)	317	315	328	318	299	285	286	279	285	257	247	235
Taltz — Worldwide revenue ($M) [Q1–Q3 10-Q & FY through FY2024]($M)	856	733		902	848	762	952	880	825	604	785	744
Taltz — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY through FY2024](%)	1.0%	-4.0%		279.3%	285.3%	257.0%	21.0%	18.0%	17.0%	15.0%	11.0%	9.0%
Other Immunology medicines — U.S. revenue ($M)($M)1	251	202	187	190	152	102	102	93.8	60.4	50.1	226	0
Other Immunology medicines — Outside U.S. revenue ($M)($M)	310	269	302	271	256	225	238	212	197	180	773	11.4
Neuroscience — U.S. revenue ($M)($M)2	325	293	320	240	248	189	224	201	192	163	183	207
Neuroscience — Outside U.S. revenue ($M)($M)	104	89	139	76.1	96	83	170	151	148	226	180	1,561
Neuroscience — Worldwide revenue ($M) [legacy total]($M)	429	382		316	344	272		352	340	389		1,768
Other therapeutic areas — U.S. revenue ($M)($M)2	84	56	77	44.8	83	100	46	107	52.2	45.7	95.2	124
Other therapeutic areas — Outside U.S. revenue ($M)($M)	122	130	114	292	119	113	145	156	155	196	161	152
Other therapeutic areas — Worldwide revenue ($M) [legacy total]($M)	205	187		337	202	213		263	208	242		276
Non-major products combined ('Other products' in MD&A) — Worldwide revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)3	3,322	2,910	6,017	6,027	5,488	5,416	1,536	682	644	610	698	590
Non-major products combined — U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)	1,842	1,517	3,507	3,301	3,204	2,871	492	326	279	208	203	176
Non-major products combined — Outside U.S. revenue ($M) [Q1–Q3 10-Q & FY 10-K]($M)	1,481	1,393	2,510	2,726	2,285	2,545	1,044	357	364	402	496	413
Non-major products combined — Worldwide revenue growth YoY (%) [Q1–Q3 10-Q & FY 10-K](%)	16.0%	14.0%		6.0%	-3.0%	196.2%		29.0%	2.0%	1.0%		17.0%
Humalog (insulin lispro) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							620	535	632	539	367	395
Humalog (insulin lispro) — U.S. revenue ($M) [legacy]($M)							406	324	435	338	168	194
Humalog (insulin lispro) — Outside U.S. revenue ($M) [legacy]($M)							214	211	197	200	199	201
Humalog (insulin lispro) — Worldwide revenue YoY (%) [legacy](%)							69.0%	35.0%	43.0%	17.0%	-33.0%	-12.0%
Humulin (human insulin) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							280	207	224	206	188	207
Humulin (human insulin) — U.S. revenue ($M) [legacy]($M)							171	150	169	153	122	146
Humulin (human insulin) — Outside U.S. revenue ($M) [legacy]($M)							109	57.1	54.2	53.1	66.6	61.2
Humulin (human insulin) — Worldwide revenue YoY (%) [legacy](%)								61.2%	9.0%	-18.0%		-13.0%
Basaglar (insulin glargine) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							177	162	181	158	185	180
Basaglar (insulin glargine) — U.S. revenue ($M) [legacy]($M)							102	85.5	105	83.2	113	111
Basaglar (insulin glargine) — Outside U.S. revenue ($M) [legacy]($M)							75.4	76.2	75.6	74.3	71.8	68.2
Basaglar (insulin glargine) — Worldwide revenue YoY (%) [legacy](%)								-10.0%	17.0%	-25.0%		-7.0%
Cyramza (ramucirumab) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							259	236	249	230	254	224
Cyramza (ramucirumab) — U.S. revenue ($M) [legacy]($M)							112	107	116	107	98.7	88
Cyramza (ramucirumab) — Outside U.S. revenue ($M) [legacy]($M)							146	129	133	123	155	136
Cyramza (ramucirumab) — Worldwide revenue YoY (%) [legacy](%)								5.0%	-4.0%	-3.0%	-9.0%	-3.0%
Erbitux (cetuximab) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							175	152	156	145	150	154
Erbitux (cetuximab) — U.S. revenue ($M) [legacy]($M)							154	133	143	132	131	134
Erbitux (cetuximab) — Outside U.S. revenue ($M) [legacy]($M)							21.1	18.7	13	12.5	19.6	19.9
Erbitux (cetuximab) — Worldwide revenue YoY (%) [legacy](%)								-1.0%	-4.0%	11.0%		6.0%
Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							250	203	192	226	186	169
Emgality (galcanezumab) — U.S. revenue ($M) [legacy]($M)							156	141	138	125	128	127
Emgality (galcanezumab) — Outside U.S. revenue ($M) [legacy]($M)							94	61.6	54.4	101	57.8	42.1
Emgality (galcanezumab) — Worldwide revenue YoY (%) [legacy](%)								20.0%	13.0%	46.0%	6.0%	54.6%
Olumiant (baricitinib) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							262	251	228	217	243	231
Olumiant (baricitinib) — U.S. revenue ($M) [legacy]($M)							68.9	68.9	44.5	46.3	66.7	65.7
Olumiant (baricitinib) — Outside U.S. revenue ($M) [legacy]($M)							193	182	183	171	177	166
Olumiant (baricitinib) — Worldwide revenue YoY (%) [legacy](%)								8.0%	4.0%	-5.0%	18.0%	27.0%
Tyvyt (sintilimab) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							136	150	123	117	114	115
Tyvyt (sintilimab) — U.S. revenue ($M) [legacy]($M)							0	0	0	0	0	0
Tyvyt (sintilimab) — Outside U.S. revenue ($M) [legacy]($M)							136	150	123	117	114	115
Tyvyt (sintilimab) — Worldwide revenue YoY (%) [legacy](%)								30.0%	19.0%	91.0%	98.0%	50.0%
Alimta (pemetrexed) — Worldwide revenue ($M) [legacy separate disclosure]($M)3											44.9	53.5
Alimta (pemetrexed) — U.S. revenue ($M) [legacy]($M)											13.7	21.2
Alimta (pemetrexed) — Outside U.S. revenue ($M) [legacy]($M)											31.1	32.3
Alimta (pemetrexed) — Worldwide revenue YoY (%) [legacy](%)											-81.0%	-55.0%
Forteo (teriparatide) — Worldwide revenue ($M) [legacy separate disclosure]($M)3								118	69.9	61.3	116	146
Forteo (teriparatide) — U.S. revenue ($M) [legacy]($M)								71.7	31.5	21.7	66.3	101
Forteo (teriparatide) — Outside U.S. revenue ($M) [legacy]($M)								46.4	38.5	39.5	50.1	45.2
Forteo (teriparatide) — Worldwide revenue YoY (%) [legacy](%)								-19.0%	-53.0%	-50.0%		-17.0%
Cialis (tadalafil) — Worldwide revenue ($M) [legacy separate disclosure]($M)3								91.5	87.7	139	78.8	86.8
Cialis (tadalafil) — U.S. revenue ($M) [legacy]($M)								4.20	7.50	5.90	4.50	4.90
Cialis (tadalafil) — Outside U.S. revenue ($M) [legacy]($M)								87.3	80.2	133	74.2	82
Cialis (tadalafil) — Worldwide revenue YoY (%) [legacy](%)								5.0%	-24.0%	39.0%		-25.0%
Zyprexa (olanzapine) — Worldwide revenue ($M) [legacy separate disclosure]($M)3							8.80	31.7			43.8	1,481
Zyprexa (olanzapine) — U.S. revenue ($M) [legacy]($M)							1.50	1.90			10.3	49.9
Zyprexa (olanzapine) — Outside U.S. revenue ($M) [legacy]($M)							7.30	29.8			33.5	1,432
Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy](%)								-98.0%				73.4%
Trajenta (linagliptin) — Worldwide revenue ($M) [legacy separate disclosure]($M)								91.7	76.6	88.9	102	95.2
Baqsimi (nasal glucagon) — Worldwide revenue ($M) [legacy separate disclosure]($M)2							4.30	13.4	12.4		19.2	13.1
Baqsimi (nasal glucagon) — U.S. revenue ($M) [legacy]($M)							1.10	8.20	3.30		12.6	3.80
Baqsimi (nasal glucagon) — Outside U.S. revenue ($M) [legacy]($M)							3.30	5.10	9		6.50	9.30
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure]($M)3											0	0
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy]($M)											0	0
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Outside U.S. revenue ($M) [legacy]($M)											0	0
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy](%)											-100.0%	-100.0%
Retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy](%)											14.0%	56.0%
Diabetes therapeutic area — Worldwide revenue ($M) [legacy grouping through FY2023]($M)2												4,720
Diabetes — U.S. revenue ($M) [legacy]($M)												3,460
Diabetes — Outside U.S. revenue ($M) [legacy]($M)												1,260

Consolidated sales rebates and discounts liability ($M)($M)	21,122	17,547	17,382	17,620	14,537	11,550	11,539	12,430	12,447	9,430	11,689	11,522

Total research and development expense ($M)($M)2	3,819	3,510	3,802	3,466	3,336	2,734	3,023	2,734	2,711	2,523	2,562	2,409
Early-stage research and discovery expense ($M)($M)	1,450	1,266	1,485	1,250	1,156	990	1,044	995	1,025	852
Late-stage clinical development expense ($M)($M)	2,368	2,244	2,316	2,216	2,180	1,744	1,979	1,739	1,686	1,671
Acquired in-process research and development (IPR&D) charges ($M)($M)1	2,776	584	529	656	154	1,572	189	2,826	154	111	620	2,980
Cash paid for IPR&D and development milestones ($M)($M)	3,282	204	424	720	107	1,757	251	2,820	178	96.5	580	3,031
Asset impairment, restructuring and other special charges ($M)($M)	703	279	84.1	365	0	35	344	81.6	435	0	68	0

GAAP gross margin ($M)($M)1	19,706	16,222	15,920	14,593	13,110	10,504	11,129	9,268	9,133	7,095	7,565	7,639
GAAP gross margin (% of revenue)(%)	85.8%	81.9%	82.5%	82.9%	84.3%	82.5%	82.2%	81.0%	80.8%	80.9%	80.9%	80.4%
Non-GAAP gross margin ($M)($M)2	19,831	16,350	16,044	14,712	13,232	10,627	11,265	9,408	9,272	7,234	7,694	7,764
Non-GAAP gross margin (% of revenue)(%)	86.3%	82.6%	83.2%	83.6%	85.0%	83.5%	83.2%	82.2%	82.0%	82.5%	82.3%	81.7%
Amortization of intangible assets in cost of sales ($M)($M)	125	128	124	119	122	123	136	139	139	139	129	125
Non-GAAP net income ($M)($M)1	7,493	7,663	6,771	6,312	5,679	3,004	4,806	1,065	3,541	2,335	2,249	94.8
Non-GAAP diluted earnings per share ($)($)	8.38	8.55	7.54	7.02	6.31	3.34	5.32	1.18	3.92	2.58	2.49	0.10
GAAP effective tax rate (%)(%)1	23.3%	16.4%	19.7%	22.8%	16.5%	20.2%	12.5%	38.9%	15.6%	11.6%	12.7%	113.4%
Non-GAAP effective tax rate (%)(%)	22.2%	16.5%	19.7%	17.7%	16.5%	20.2%	13.2%	37.6%	16.5%	11.9%	13.1%	84.6%

Total inventories, net ($M)($M)2	16,793	14,529	13,744	12,180	11,014	9,311	7,589	7,460	6,482	6,102	5,773	4,901
Total inventories, gross (FIFO cost before LIFO reserve, $M)($M)3	16,755	14,492	13,701	12,219	11,015	9,282	7,526	7,386	6,394	6,005	5,670
Finished goods inventory ($M)($M)	2,630	2,273	1,931	1,547	1,355	1,298	1,221	1,114	811	700	792
Work in process (WIP) inventory ($M)($M)	9,997	8,456	8,183	7,275	6,509	5,296	3,979	4,035	3,706	3,612	3,249
Raw materials and supplies inventory ($M)($M)	4,128	3,763	3,587	3,397	3,151	2,687	2,326	2,237	1,876	1,694	1,630
LIFO inventory valuation reserve ($M)($M)	-38	-37	-43	38.4	1.40	-29.3	-63	-73.4	-87.7	-96.5	-102
Property and equipment, net ($M)($M)1	29,286	26,540	24,675	22,316	20,530	18,474	17,102	16,172	14,829	13,624	12,914	11,863
Accumulated depreciation ($M)($M)	13,103		12,560	12,411	12,554	12,147	11,789	11,816	11,428	11,235	11,099	10,768
Capital expenditures (additions to property and equipment, $M)($M)	2,933	2,326	2,547	2,087	1,697	1,510	1,496	1,351	1,225	986	1,071	970
Depreciation and amortization expense ($M)($M)	534	509	586	470	478	463	485	467	414	401	387	411
Goodwill ($M)($M)	8,849	6,130	5,898	5,898	5,771	5,771	5,770	5,768	5,768	4,940	4,940	4,085
Other intangible assets, net ($M)($M)	18,110	7,374	6,521	6,447	5,908	6,012	6,166	6,537	6,636	6,762	6,907	6,782
Prepaid income taxes ($M)($M)1	13,600	11,800	12,900	18,690	16,400		7,100				4,260	4,080
Noncurrent accrued income taxes ($M)($M)	5,461	5,289	5,875	6,294	5,684	5,371	4,061	3,879	3,497	4,189	3,849	3,468

Long-term debt, noncurrent ($M)($M)1	47,858	39,370	40,868	40,874	34,180	34,500	28,527	29,045	23,730	24,560	18,321	17,924
Short-term borrowings and current maturities of long-term debt ($M)($M)1	7,050	4,000	1,635	1,633	5,724	4,016	5,117	2,074	5,162	1,652	6,905	2,245
Commercial paper outstanding ($M)($M)	5,284	1,775	0	0	4,092	2,489	4,338	1,295	4,385	985	6,189	1,595
FX forward contracts (not designated as hedging instruments) — Long notional ($M)($M)3	17,869	13,297	14,281				8,755
FX forward contracts (not designated as hedging instruments) — Short notional ($M)($M)	10,123	5,520	9,264				8,848
FX forward contracts (net investment hedges) — Long notional ($M)($M)	246	297	67				8,909
Foreign-currency principal notes (designated as net investment hedges) — Notional ($M)($M)	3,600	3,600	6,000				5,300
Dividends paid per share ($)($)1	1.73	1.73	1.50	1.50	1.50	1.50	1.30	1.30	1.30	1.30	1.13	1.13
Cash dividends paid ($M)($M)	1,546	1,548	1,346	1,346	1,347	1,346	1,168	1,171	1,172	1,169	1,018	1,016
Cash paid for share repurchases ($M)($M)2	1,601	2,356	1,508	708	692	1,200	2,054	446	0	0	0	0
Share repurchase program total authorization ($M)($M)	15,000	15,000	15,000	15,000	15,000	15,000	15,000
Share repurchase authorization remaining ($M)($M)	7,000	8,600	10,900	12,400	13,110	13,800		1,980	2,500	2,500	2,500	2,500
Stock-based compensation expense — Pretax ($M)($M)	201	161	136	151	185	154	142	133	211	159	121	216
Employee Benefit Trust assets ($M)($M)	3,013	3,013	3,013	3,013	3,013	3,013	3,000	3,013	3,013	3,013	3,010	3,013

U.S. Personal Consumption Expenditures: Health Care — SAAR ($B)(M)	3,790	3,700	3,667	3,615	3,530	3,465	3,418	3,358	3,288	3,244	3,159	3,079

Revenue ($M)($M)13	22,974	19,799	19,292	17,601	15,558	12,729	13,533	11,439	11,303	8,768	9,353	9,499
Cost of sales ($M)($M)	3,268	3,577	3,372	3,008	2,448	2,225	2,404	2,171	2,170	1,674	1,788	1,860
Research and development ($M)($M)	3,819	3,510	3,802	3,466	3,336	2,734	3,023	2,734	2,711	2,523	2,562	2,409
Marketing, selling, and administrative ($M)($M)	3,430	2,934	3,131	2,741	2,753	2,468	2,425	2,100	2,117	1,952	1,926	1,804
Asset impairment, restructuring, and other special charges ($M)($M)	703	279	84.1	365	0	35	344	81.6	435	0	68	0
Interest income ($M) [reported separately through Q3 2025]($M)				65	40	48.3	44.3	47.8	37.3	45.8	44.5	48.9
Other — net, (income) expense ($M)($M)	269	-65	-108	-133	-90	-239	-111	62	-198	27.1	121	-23.2
Income before income taxes ($M)($M)	9,247	8,850	8,266	7,232	6,777	3,456	5,038	1,588	3,517	2,536	2,508	427
Income taxes ($M)($M)	2,152	1,454	1,629	1,650	1,116	697	629	618	550	293	319	485
Net income ($M)($M)	7,095	7,396	6,638	5,583	5,661	2,759	4,410	970	2,967	2,243	2,189	-57.4
Earnings per share — Basic ($)($)	7.95	8.27		6.22	6.30	3.07		1.08	3.29	2.49		-0.06
Earnings per share — Diluted ($)($)	7.94	8.26		6.21	6.29	3.06		1.07	3.28	2.48		-0.06
Weighted-average shares outstanding — Basic (millions)(M)	892	895		897	898	899		901	901	901		900
Weighted-average shares outstanding — Diluted (millions)(M)	894	896		899	900	901		905	904	904		900
Total assets ($M)($M)7	142,283	116,576	112,476	114,935	100,923	89,389	78,715	75,607	71,875	63,944	64,006	57,916
Total current assets ($M)($M)6	64,672	54,835	55,629	62,071	49,854	41,261	32,740	31,415	30,204	25,189	25,727	23,007
Cash and cash equivalents ($M)($M)	8,950	5,282	7,268	9,792	3,376	3,093	3,268	3,369	3,224	2,460	2,819	2,381
Short-term investments ($M) [through Q3 2025]($M)				122	170	127	155	149	140	126	109	113
Accounts receivable, net ($M)($M)	20,083	18,429	17,760	16,107	14,170	12,037	11,006	10,295	11,028	7,886	9,091	8,167
Inventories ($M)($M)	16,793	14,529	13,744	12,180	11,014	9,311	7,589	7,460	6,482	6,102	5,773	4,901
Prepaid expenses and other ($M)($M)	15,368	13,633	14,315	20,249	18,020	14,654	8,341	8,251	7,138	6,349	5,541	5,248
Other current assets ($M)($M)	86	214	147	272	68.8	72.4	266	135	142	139	150
Property and equipment, net ($M)($M)	29,286	26,540	24,675	22,316	20,530	18,474	17,102	16,172	14,829	13,624	12,914	11,863
Goodwill ($M)($M)	8,849	6,130	5,898	5,898	5,771	5,771	5,770	5,768	5,768	4,940	4,940	4,085
Other intangibles, net ($M)($M)	18,110	7,374	6,521	6,447	5,908	6,012	6,166	6,537	6,636	6,762	6,907	6,782
Deferred tax assets ($M)($M)	10,028	11,350	9,959	8,963	9,427	8,573	8,001	7,392	6,655	5,634	5,477	4,575
Sundry / long-term investments ($M)($M)	3,856	3,116	2,802	2,808	3,207	3,223	3,216	3,200	2,878	3,087	3,052	2,692
Other noncurrent assets ($M)($M)	7,482	7,231	6,992	6,432	6,225	6,075	5,720	5,122	4,904	4,708	4,990	4,912
Total liabilities ($M)3
Total current liabilities ($M)($M)4	47,741	36,634	35,228	40,141	39,020	30,068	28,376	24,674	27,121	18,598	27,293	21,998
Short-term borrowings and current maturities of long-term debt ($M)($M)	7,050	4,000	1,635	1,633	5,724	4,016	5,117	2,074	5,162	1,652	6,905	2,245
Accounts payable ($M)($M)	6,112	5,029	5,379	4,262	4,076	3,442	3,229	2,887	2,925	2,474	2,599	2,435
Income taxes payable ($M) [through Q3 2025]($M)				9,444	6,958	6,176	1,116					1,978
Other current liabilities ($M)($M)	11,659	8,699	8,457	5,215	5,077	3,770	6,397	5,580	4,249	4,199	3,281	2,585
Long-term debt ($M)($M)	47,858	39,370	40,868	40,874	34,180	34,500	28,527	29,045	23,730	24,560	18,321	17,924
Other noncurrent liabilities ($M)($M)	7,344	4,085	3,970	3,777	2,345	2,288	3,479	2,239	2,471	2,271	2,241	1,906
Total equity ($M)($M)6	33,879	31,198	26,535	23,851	18,349	15,847	14,272	14,321	13,636	12,897	10,864	11,307
Common stock ($M)($M)	588	590	590	591	592	593	592	594	594	594	594	594
Additional paid-in capital ($M)($M)	7,117	6,921	7,346	7,232	7,089	6,910	7,439	7,340	7,214	7,010	7,250	7,160
Retained earnings ($M)($M)	31,893	29,514	24,470	22,252	17,376	15,100	13,545	13,627	13,178	12,554	10,312	10,310
Accumulated other comprehensive loss ($M)($M)	-2,761	-2,833	-2,880	-3,206	-3,716	-3,775	-4,322	-4,275	-4,379	-4,300	-4,327	-3,785
Cost of common stock in treasury ($M) [through Q3 2025]($M)				-62.5	-55.4	-49.5	-49.5	-32.7	-32.7	-32.7	-44.2	-45
Noncontrolling interests ($M) [through Q3 2025]($M)				57.5	76.2	82	79.5	80.7	73.5	85.2	91.8	87
Net cash provided by operating activities ($M)($M)6	10,690	5,333	3,225	8,835	3,087	1,666	2,474	3,712	1,466	1,166	-312	2,190
Depreciation and amortization ($M)($M)	534	509	586	470	478	463	485	467	414	401	387	411
Stock-based compensation expense ($M)($M)	201	161	136	151	185	154	142	133	211	159	121	216
Net cash used for investing activities ($M)($M)1	-15,396	-3,916	-2,802	-2,983	-1,834	-3,353	-1,921	-4,005	-2,199	-1,178	-2,925	-3,081
Other investing activities, net ($M)($M)	-127	-31	56.8	-308	141	111	-678	373	105	-48.2	71.1	-666
Net cash provided by / (used for) financing activities ($M)($M)6	8,426	-3,470	-2,879	531	-1,245	1,380	-226	211	1,556	-311	3,545	572
Dividends paid to shareholders ($M)($M)	1,546	1,548	1,346	1,346	1,347	1,346	1,168	1,171	1,172	1,169	1,018	1,016
Purchases of common stock / share repurchases ($M)($M)	1,601	2,356	1,508	708	692	1,200	2,054	446	-0	-0	-0	-0
Issuances of long-term debt ($M)($M)	8,941	0	-0.20	6,706	0	6,461	-0.10	4,965	0	6,453	0.50	0
Repayments of long-term debt ($M)($M)	873	750	-0.10	0.10	778	-0	-0.20	-0			-0	-0
Net change in short-term borrowings ($M)($M)	3,509	1,775	-0.40	-4,092	1,603	-1,849	3,042	-3,089	3,400	-5,205	4,594	1,595
Other financing activities, net ($M)($M)	-4	-591	-25.1	-29.9	-31	-686	-45.9	-47.3	-8	-390	-31.6	-6.80
Effect of exchange rate changes on cash and equivalents ($M)($M)	-52	67	-67.1	32.1	275	132	-429	227	-59.6	-35.5	130	5.30
Net increase / (decrease) in cash and cash equivalents ($M)($M)	3,668	-1,986	-2,524	6,416	283	-175	-101	145	763	-358	438	-314

22 metrics have no data in the last 12 quarters — .

Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).

Methodology and excluded metrics

Fiscal calendar: Eli Lilly and Company operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026).
Core operational & financial KPIs (Groups 1–5) cover: (1) Revenue Disaggregation by Product ($60,958M in FY25) vs. Collaboration & Other ($4,221M in FY25), Geography (U.S. $43,481M vs. Outside U.S. $21,698M across Europe $11,558M, Japan $2,132M, China $1,951M & Rest of World $6,057M), and Volume / Realized Price / Foreign Exchange Revenue Growth Drivers across Worldwide, U.S., and Outside U.S. (42 periods FY17–FY26Q2; Q2 2026 WW +48% driven by +52% volume and -6% price); (2) Therapeutic Area & Medicine Revenue across Cardiometabolic Health (Mounjaro $9,943M & Zepbound $4,928M in Q2 2026; $22,965M & $13,542M in FY25, plus Trulicity, Jardiance & Other Cardiometabolic), Oncology (Verzenio $1,474M in Q2 2026; $5,723M in FY25), Immunology (Taltz), Neuroscience, and 18 legacy/established medicines & historical Elanco Animal Health segment; (3) U.S. Gross-to-Net (GTN) Rebates, Discounts & Returns Liability ($21,122M at Q2 2026; 96% U.S.) and full 10-year U.S. GTN Rollforward ($54,757M GTN provision and $48,885M cash rebate payments in FY25), and U.S. Portfolio List (+2.9%) vs. Net Price Realized (39% of list in FY25); (4) R&D Pipeline Expense Split between Early-Stage Research/Discovery ($4,881M in FY25) and Late-Stage Clinical Development ($8,456M in FY25), Acquired IPR&D charges ($2,910M in FY25), Advertising ($2,900M / 5.0% of revenue in FY25), and Restructuring/Impairment; and (5) GAAP vs. Non-GAAP Gross Margin (84.8% GAAP / 85.4% Non-GAAP in Q2 2026), Non-GAAP Net Income & Diluted EPS ($8.41 in Q2 2026; $24.21 in FY25), GAAP vs. Non-GAAP Effective Tax Rates, Current & Deferred Federal/Foreign Taxes, Deferred Tax Assets by attribute, and Unrecognized Tax Benefits ($5,082M at FY25).
Groups 6–9 cover Manufacturing, Inventory, PP&E, Intangibles & Leases (LIFO/FIFO Inventories $16,793M net at Q2 2026 including $9,997M WIP, $1,500M pre-launch capitalized inventory, Gross PP&E $37,235M at FY25 including $13,013M Construction in Progress, Geographic Long-Lived Assets across U.S. $18,764M & Ireland $4,321M, Goodwill $8,849M, Other Intangibles $18,110M net with 5-year amortization schedule, and Operating Leases), Debt, Derivatives & Capital Return ($47,858M long-term debt & $5,284M commercial paper at Q2 2026, $17,869M long / $10,123M short FX forward contracts, Dividends, Share Repurchases, SBC & Employee Benefit Trust), Workforce, Compensation, Form 11-K 401(k) & Defined Benefit Pensions (50,000 employees, 23,000 outside U.S., 12,000 in R&D, 9% turnover, 85 training hours, CEO pay ratio 293:1, $15.62B Lilly 401(k) Plan & $634.8M Puerto Rico Savings Plan, and $14.26B Pension PBO / $14.82B Plan Assets across 6 asset classes), and Lilly 30x30 Global Health Reach (40M people in FY25) & Environmental/Safety KPIs (79.3% renewable electricity, 96.8% water recycle rate, Scope 1/2/3 GHG emissions).
No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'between 16% and 24% wholesaler revenue concentration' and 'less than 1% product returns / prior-period GTN adjustments' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Data updated 2026-10-25.

Every KPI on its own page

Full history, chart, sources and a citation for each metric

ELI LILLY & Co (LLY) operating KPIs

KPIs

Every KPI on its own page

Revenue Disaggregation & Volume / Price / FX Growth Drivers

Therapeutic Area & Medicine Revenue (Key Products & Legacy Portfolio)

Gross-to-Net (GTN) Rebates, Discounts & U.S. Pricing

R&D Pipeline Stage Breakdown, IPR&D & Commercial Expenses

GAAP vs. Non-GAAP Profitability & Income Tax Footnotes

Manufacturing, Inventory, PP&E, Intangibles & Lease Footnotes

Debt, Derivatives, Share Repurchases & Stock-Based Compensation

Workforce, Compensation, 401(k) Plans (Form 11-K) & Defined Benefit Pensions

Global Health Access, Environmental & Safety KPIs

Industry & Macroeconomic Benchmarks (BEA, Census & BLS via FRED)

Consolidated Financial Statements (Postgres DB)